BUHLMANN News

Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy

Flow CAST® Assay: Patil, S.  Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy.  Journal of Allergy and Clinical Immunology Nov 2019;  DOI: 10.1016/j.jaci.2019.07.028. Highlights from this Publication “Early decreases in basophil sensitivity to Ara h 2 correlate with SU. Basophil AUC rebounds after avoidance in subjects with TD.
Continue Reading

External Quality Assessment Scheme for Basophil Activation Test

We are pleased to inform you that the first External Quality Assessment (EQA) Scheme for Basophil Activation Test (BAT) is now available.

Continue Reading

Use of basophil activation in oral immunotherapy

An outstanding research paper was published in the top rated Journal of Allergen and Clinical Immunology which evaluated the performance of basophil activation as a biomarker in monitoring clinical efficacy of oral peanut immunotherapy in a clinical trial.

Continue Reading

CALEX Cap Promotion

BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design
Continue Reading

Protected: Historical Overview of Ganglioside Antibodies

There is no excerpt because this is a protected post.

Continue Reading

LabSense News Q1 2020 Edition

In this "Q1 2020 Edition"of BUHLMANN's LabSense News, we are proud to introduce Quantum Blue® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid test portfolio. Check out a new video for Flow CAST® basophil activation test (BAT), view recent BÜHLMANN assay citations, and read an interesting white paper for our BÜHLMANN GanglioCombi® MAG ELISA. 
Continue Reading

Faecal Calprotectin Predicts Endoscopic and Histological Activity

BÜHLMANN fCAL® ELISA Citation Lara Hart et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis, Journal of Crohn's and Colitis, Volume 14, Issue 1, January 2020, DOI: doi.org/10.1093/ecco-jcc/jjz107 READ CITATION BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use. Health Canada License: 80726 This citation describes applications that are outside of
Continue Reading

Neuroimmunology History

Page 1 of 25 1 2 3 … 25 »Sorry,You have not added any story yet References Chiba A et al. Latov N et al Ilyas, AA et al.
Continue Reading

Quantum Blue®Anti-Infliximab and Anti-Adalimumab Tests Now Available

New Quantum Blue® TDM Assays BÜHLMANN is proud to introduce Quantum Blue® Anti-Infliximab (RUO) and Anti-Adalimumab (RUO) to the TDM rapid test portfolio.  These new assays together with the infliximab and adalimumab trough level rapid tests offer the complete package for infliximab and adalimumab TDM testing on the popular Quantum Blue® platform. BÜHLMANN Quantum Blue®
Continue Reading

ECCO 2020 Poster – IBDoc Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)

IBDoc® Citation: Avery, P. et. al. N05: IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH).  ECCO 2020, Feb 12-15. Highlights from this Publication “ …This data also helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments....” Read Citation Health
Continue Reading